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Transcriptome profiling of 
monocytes from XLA patients 
revealed the innate immune 
function dysregulation due to the 
BTK gene expression deficiency
Hoda Mirsafian1, Adiratna Mat Ripen2, Wai-Mun Leong1, Chai Teng Chear2,  
Saharuddin Bin Mohamad1,3 & Amir Feisal Merican1,3
X-linked agammaglobulinemia (XLA) is a rare genetic disorder, caused by mutations in BTK (Bruton’s 
Tyrosine Kinase) gene. Deep high-throughput RNA sequencing (RNA-Seq) approach was utilized 
to explore the possible differences in transcriptome profiles of primary monocytes in XLA patients 
compared with healthy subjects. Our analysis revealed the differences in expression of 1,827 protein-
coding genes, 95 annotated long non-coding RNAs (lncRNAs) and 20 novel lincRNAs between XLA 
patients and healthy subjects. GO and KEGG pathway analysis of differentially expressed (DE) protein-
coding genes showed downregulation of several innate immune-related genes and upregulation of 
oxidative phosphorylation and apoptosis-related genes in XLA patients compared to the healthy 
subjects. Moreover, the functional prediction analysis of DE lncRNAs revealed their potential role in 
regulating the monocytes cell cycle and apoptosis in XLA patients. Our results suggested that BTK 
mutations may contribute to the dysregulation of innate immune system and increase susceptibility 
to apoptosis in monocytes of XLA patients. This study provides significant finding on the regulation of 
BTK gene in monocytes and the potential for development of innovative biomarkers and therapeutic 
monitoring strategies to increase the quality of life in XLA patients.
X-linked agammaglobulinemia (XLA) is one of the inherited forms of Primary Immunodeficiency Diseases 
(PIDs)1. It is caused by mutations in the BTK (Bruton’s Tyrosine Kinase) gene, which results in defective devel-
opment and maturation of B cell within the bone marrow and a considerable decrease or complete absence 
of mature B cells in peripheral blood2. Due to the absence of mature B cells, XLA patients have significantly 
decreased levels of all major immunoglobulins in the serum and consequently, would be subjected to severe and 
chronic bacterial infections3. The BTK expression is not restricted to B cells, it is also expressed in myeloid cells 
such as neutrophils4, natural killer (NK) cells5, and monocytes6. The significance of BTK for macrophage function 
was first seen in X-linked immunodeficient (XID) mice infected with microfilaria7. The experiments showed a 
delayed microfilaria clearance together with low levels of IL-12A (Interleukin 12A), IL-1 (Interleukin 1) and TNF 
(Tumor Necrosis Factor) production as well as decrease in NO (Nitric oxide) production in XID mice7. Similarly, 
Schmidt and colleagues showed that in primary macrophages, BTK was activated by TLR4 (Toll-like Receptor 4) 
and is essential for normal TLR-induced IL-10 (Interleukin 10) production in various populations of mac-
rophages8. Additionally, BTK also plays a crucial role in initiating TLR3 signaling in BTK deficient macrophages9. 
In the absence of BTK, TLR3-induced PI3K (Phosphoinositide 3-Kinase), AKT (V-Akt Murine Thymoma Viral 
Oncogene Homolog 1) and MAPK (MAP Kinase Phosphorylation) signaling as well as activation of NFκB 
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(Nuclear Factor Kappa B), IRF3 (Interferon Regulatory Factor 3), and AP-1 transcription factors were defective9. 
Further investigations on the human monocytic THP1 cell line showed interactions of TLR8 and TLR9 with BTK, 
in which defective BTK leads to impaired TLR8 and TLR9 signaling and causes susceptibility of XLA patients to 
viral infections10. It has also been reported that BTK contributed in TLR4 signaling to NFκB, and may also involve 
in signaling by ligands for TLR2, TLR6, TLR8, and TLR9 and also with MYD88 (Myeloid Differentiation Primary 
Response 88), MAL (MyD88-Adapter-Like) and IRAK1 (Interleukin 1 Receptor Associated Kinase 1)11, 12. 
The decreased chemotaxis and defective FcγR (Fc-gamma Receptors), CR1 (Complement Receptor 1) and CR3 
(Complement Receptor 3)-mediated phagocytosis has also been reported in monocytes from XLA patients com-
pared to healthy subjects13.
In addition to the protein coding genes, long non-coding RNAs (lncRNAs) have also been shown to play 
important roles in immune cell development and processes such as anti-viral responses, NFκB signaling, and 
inflammatory responses14, 15. lncRNAs are the biggest class of non-coding RNAs in mammalians, having more 
than 200 nucleotides length and without coding potential16. The lncRNAs dysregulated expression has been also 
reported in many human disease, such as cancer17, 18, neurological disorders19, autoimmune disease20, 21, and 
microbial susceptibility22.
Monocytes are essential components of the innate immune system. They are produced from a common mye-
loid progenitor cells in the bone marrow and circulate in the blood vessels for short times. During inflammatory 
conditions, they move into peripheral tissues, differentiating into macrophages and dendritic cells. The effect of 
primary monocyte with BTK deficient in XLA patients is not well studied. There is no or limited data exist on the 
genome-wide transcriptome expression profile of primary monocytes in XLA patients. In addition, the molecu-
lar mechanisms underlying the functions of lncRNAs in primary monocytes of XLA have not been studied yet. 
We recently published a gene reference catalogue and lncRNAs landscape of human primary monocytes from 
healthy subjects23, 24. In this study, we performed deep high-throughput RNA sequencing (RNA-Seq) analysis 
on primary monocytes from XLA patients and healthy subjects to investigate the effect of BTK gene expression 
deficiency on innate immune function of XLA patients. We identified the set of protein-coding genes and lncR-
NAs which were differentially expressed (DE) between XLA patients and healthy subjects. Gene Ontology (GO) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses predicted the functions of these DE 
protein-coding genes and lncRNAs in primary monocytes of XLA patients.
Results
Transcriptome profiling. We performed deep RNA-Seq of primary monocytes from healthy subjects 
and XLA patients. The patients were diagnosed to have XLA with absence or low circulating B cells, low serum 
immunoglobulin isotypes and deficient of BTK protein expression in their monocytes. Molecular genetic tests 
revealed BTK gene mutations in all patients. Novel BTK invariant splice site mutation was identified in one of the 
patients25. The history of the patient’s serum immunoglobulin levels before receiving intravenous human immu-
noglobulin (IVIG) therapy, and the nucleotide change that occurred in each patient and its consequences in the 
protein synthesis is shown in Table 1.
RNA was extracted from classical monocytes (CD14++CD16−) isolated from peripheral blood mononu-
clear cells (PBMCs) using a negative selection method. The purified RNA was used to carry out poly-adenylated 
paired-end RNA sequencing using Illumina HiSeq 2000 platform. After discarding adaptor sequences and 
low-quality sequences, we obtained approximately 1.2 million reads from all samples. The trimmed reads were 
mapped to human reference genome (Ensembl GRCH38.79) and transcripts were assembled using aligned reads. 
The transcripts from each XLA patients and healthy subjects were then separately merged to form two sets of 
single non-redundant transcripts. The expression levels of transcripts were quantified across each dataset. By 
applying an FPKM > 0.1 threshold, we have identified the expression of total 11,777 protein-coding genes and 
3,363 lncRNAs in XLA patients, and 11,644 protein-coding genes and 3,190 lncRNAs in healthy subjects. Using 
multi-step mapping and filtering criteria, the expression of 430 and 380 potential novel lincRNAs were also iden-
tified in XLA patients and healthy subjects, respectively.
Ig levels at diagnosis (mg/dL) Mutations
Patient
Age 
(years)
Age at 
onset 
(years)a
Age at 
diagnosis 
(years)b
Family 
historyc IgG IgM IgA
CD19+ 
(%)
BTK 
expression Nucleotide Protein
Protein 
Domain
P1 12 1 4 − N/A N/A N/A 1 (12−22) 7.7% c.1888A > T p.M630L Kinase
P2 13 1 6 + 41(550−1200) <12(40−95) 48 (60–170)
0 
(12−22) 6% IVS9 + 1 G > C
Skipping of 
exon 9
SH3 & 
SH2
P3 18 2 7 − 91.1 (550−1200)
11.3 
(40−95)
UD 
(60−170)
0 
(12−22) 0.04%
g.34430_34447 
delCAAAGTCATGATgtgagt
p.A446_
N451 ins(28 
amino acids)
Kinase
Table 1. Clinical and immunological data of the XLA patients. N/A, not available. UD, undetectable. aAge at 
the which an individual acquires, develops, or first experiences a condition or symptoms of a disease. bAge at 
the start of intravenous immunoglobulin replacement. c“ + ”, indicates that family members [boy (s)] died at a 
young age because of infection. dNormal expression is >94%.
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Differentially expressed (DE) protein-coding genes and lncRNAs in XLA patients compared to 
healthy subjects. The differential gene expression analysis between XLA patients and healthy subjects was 
conducted using Cuffdiff and the genes with q-value ≤ 0.01 and log2 fold-change ≥ 1 or ≤ −1 were defined as dif-
ferentially expressed (DE). Using these criteria, a total of 1,827 DE protein-coding genes, 95 DE annotated lncR-
NAs and 20 DE novel long intergenic non-coding RNAs (lincRNAs) were identified in XLA patients compared to 
the healthy subjects. Figure 1 shows the hierarchical clustering of the expression patterns of DE protein-coding 
genes and DE lncRNAs between XLA patients and healthy subjects.
Differentially expressed (DE) protein-coding genes. Out of the 1,827 DE protein-coding genes, 
859 genes were upregulated and 968 genes were downregulated in XLA patients compared to the healthy sub-
jects (Supplementary Table S1). The expression of BTK was detected to be significantly downregulated (log2 
fold-change < −7) in XLA patients compared to healthy subjects. The functional consequences of identified 
DE protein-coding genes in XLA patients compared to healthy subjects were characterized through GO enrich-
ment and KEGG pathway analysis (Fig. 2, Supplementary Table S2). The significant GO biological process terms 
for upregulated genes were related to mitochondrial function and organization including: “oxidative phospho-
rylation”, mitochondrial ATP synthesis coupled to electron transport”, and “electron transport chain”, as well 
as “apoptotic” process and “response to oxidative stress” (Fig. 2a). The expression of several apoptosis-related 
genes such as BAX (BCL2 Associated X Protein) and BAD (BCL2 Associated Agonist of Cell Death) and oxida-
tive stress response genes such as SOD1 (Superoxide Dismutase 1, Soluble), GPX1 (Glutathione Peroxidase 1), 
 GPX4 (Glutathione Peroxidase 4), PRDX1 (Peroxiredoxin 1), PRDX5 (Peroxiredoxin 5) were observed to be 
significantly upregulated in XLA patients compared to healthy subjects. However, the GO biological process 
terms for downregulated genes were significantly related to monocytes immune system functions including: 
“intracellular signaling cascade”, “immune response” and “innate immune response” (Fig. 2b). Furthermore, the 
KEGG pathway analysis revealed that the upregulated genes were enriched in 9 pathways, most significantly 
in “Oxidative phosphorylation” (Fig. 2c). The oxidative phosphorylation system consists of five protein com-
plexes namely; I (NDUF; NADH: Ubiquinone Oxidoreductase), II (SHD; Src Homology 2 Domain Containing 
Transforming Protein D), III (UQCR; Ubiquinol-Cytochrome C Reductase), IV (COX; Cytochrome C Oxidase), 
and V (ATP; Adenosine Triphosphate). In this study, the upregulation of the several components of complexes I, 
III, IV and V were observed in primary monocytes of XLA patients compared to the healthy subjects (Table 2). 
The GO analysis also revealed that the downregulated genes were enriched in 29 pathways, most significantly in 
several immune-related pathways such as “Fc gamma R-mediated phagocytosis”, “Chemokine signaling path-
way”, “Toll-like receptor signaling pathway” and “MTOR signaling pathway” (Fig. 2d). The core downregulated 
Figure 1. Hierarchical clustering of DE protein-coding genes and DE lncRNAs in primary monocytes of XLA 
patients compared to healthy subjects. (a) DE protein-coding genes (b) DE annotated lncRNAs and (c) DE 
novel lincRNAs. The green and orange shades indicate the expression above and below the relative expression, 
respectively, across all samples.
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genes contributing to the enrichment of the immune-related pathways in primary monocyte of XLA patients is 
presented in Table 3.
Gene interaction network of DE protein-coding genes. To explore the dysregulated gene interactions 
in primary monocytes of XLA patients, the interaction networks were generated for DE protein-coding genes 
which were significantly enriched in upregulated and downregulated KEGG pathways in XLA patients compared 
to healthy subjects (Fig. 3). The network contained 1,601 interactions between 78 upregulated and 103 downreg-
ulated genes.
Differentially expressed (DE) long non-coding RNAs (lncRNAs). The total of 95 DE annotated lncR-
NAs were detected in primary monocytes of XLA patients compared to healthy subjects in which 56 and 39 lncR-
NAs were upregulated and downregulated, respectively (Supplementary Table S3). Several lncRNAs which were 
known to be involved in the regulation of gene expression, cell cycle and apoptosis were detected among DE lncR-
NAs in primary monocytes of XLA patients. These lncRNAs include: HOTAIRM1 (HOXA Transcript Antisense 
Figure 2. The GO and KEGG pathway analysis of DE protein-coding genes in primary monocytes of XLA 
patients compared to healthy subjects. The significant GO biological process terms (adj.P-value < 0.01) enriched 
for (a) upregulated genes, and (b) downregulated genes. The number of identified DE protein-coding genes 
enriched in each GO terms is depicted above bars of x-axis in the figure. The significant KEGG pathway terms 
enriched for (c) upregulated genes and (d) downregulated genes. Each statistical significance value (adj.p-value) 
was negative log-10 base transformed.The numbers in the brackets indicated the total number of genes available 
in the KEGG database for each pathway terms. The number of identified DE protein-coding genes enriched in 
each KEGG pathways is depicted above bars of x-axis in the figure.
Oxidative Phosphorylation Pathway (P-value: 6.50E-18; Adj.P-value = 5.20E-16)
Oxidative Phosphorylation 
system subunits Gene Name
Complex I: NADH 
dehydrogenase
NDUFA1, NDUFA12, NDUFA2, NDUFA3, NDUFA4, NDUFA6, NDUFA8, NDUFAB1, 
NDUFB11, NDUFB4, NDUFB5, NDUFB7, NDUFB8, NDUFS4, NDUFS5, NDUFS6, NDUFS7
Complex III: Cytochorom c 
reductase UQCR10, UQCRB, UQCRFS1, UQCRH, UQCRHL
Complex IV: Cytochorom c 
oxidase COX14, COX17, COX4I1, COX5A, COX5B, COX6B1, COX6C, COX7A2, COX7C
Complex V: ATPase ATP1A3, ATP5D, ATP5E, ATP5G2, ATP5G3, ATP5H, ATP5I, ATP5J, ATP6V0B, ATP6V0E1, ATP6V1F, ATPIF1
Table 2. The upregulated genes involved in Oxidative Phosphorylation pathway in primary monocytes of the 
XLA patients compared to healthy subjects.
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RNA, Myeloid-Specific 1)26, DANCR (Differentiation Antagonizing Non-Protein Coding RNA)27, GAS5 (Growth 
Arrest Specific 5)28, LINC-PINT (Long Intergenic Non-Protein Coding RNA, P53 Induced Transcript)29, HEIH 
(Hepatocellular Carcinoma Associated Transcript)30 and RMRP (RNA Component Of Mitochondrial RNA 
Processing Endoribonuclease)31 which were upregulated and, TUG1 (Taurine Upregulated 1)32, which was down-
regulated in XLA patients compared to the healthy subjects. In addition, expression of the 20 DE novel lincRNAs 
were identified between XLA patients and healthy subjects. Among the 20 DE novel lincRNAs, 5 lincRNAs were 
upregulated and 15 lincRNAs were downregulated in XLA patients compared to healthy subjects, respectively 
(Supplementary Table S4).
DE lncRNAs co-located with protein-coding genes. lncRNAs have been reported to coordinate the 
regulation of neighboring protein-coding genes (co-located genes). To identify the potential function of the 
identified DE lncRNAs, the protein-coding genes which genomic locations within ~5 kb upstream and ~1 kb 
downstream of the DE lncRNAs and which may extend to 1000 kb in both directions were searched. The anal-
ysis revealed that out of 95 DE annotated lncRNAs, 85 lncRNAs were corresponded to 144 protein-coding 
genes. Moreover, among the 20 DE novel lincRNAs, 18 novel lincRNAs were linked to 28 protein-coding 
genes (Supplementary Table S5). Majority of DE lncRNAs region-gene associations were found to be dis-
tal binding events while approximately only 9% regions were within 5 kb of transcription start sites (TSS) 
(Supplementary Fig. S1).
Next, the function of DE lncRNAs was examined based on GO enrichment and KEGG pathway analysis of 
their co-located genes (Fig. 4, Supplementary Table S2). The GO enrichment analysis based on biological process 
demonstrated that the DE annotated lncRNAs co-located genes were mainly involved in “reproductive process”, 
“positive regulation of cell proliferation” and “induction of apoptosis by extracellular signals” (Fig. 4a). On the 
other hands, the DE novel lincRNAs co-located genes were related to “regulation of cell differentiation” and 
“regulation of cell activation” (Fig. 4b). The KEGG pathway analysis revealed that the DE annotated lncRNAs 
co-located genes were significantly involved in “Metabolic pathways”, and “Cytokine- cytokine receptor interac-
tion” (Fig. 4c). While the novel lincRNAs co-located genes were related to “Focal adhesion” and “Regulation of 
actin cytoskeleton” (Fig. 4d).
Besides that, we examined whether any DE lncRNAs co-located genes was differentially expressed in XLA 
patients compared to healthy subjects. The comparison of the DE annotated and novel lncRNAs co-located 
genes with DE protein-coding genes led to identification of 23 genomically co-located DE protein-coding genes 
(Supplementary Table S6). For instance, DE annotated lncRNAs; HOTAIRM1, DANCR and GAS5 were co-located 
with DE protein-coding genes: HOXA1, USP46, ZBTB48 respectively, which are involved in regulating the gene 
expression, morphogenesis and differentiation, ubiquitin protease activity, and MHC II promoter compotes. The 
results also indicated that DE novel lincRNAs TCONS_00030433, TCONS_00041961 and TCONS_00295657 
were co-located with DE protein-coding genes VAV3 (Vav Guanine Nucleotide Exchange Factor 3) - involve 
Pathway Terms P-value Adj.P-value Gene Name
Fc gamma R-mediated phagocytosis 1.10E-07 2.60E-06
FCGR2A, ASAP1, GAB2, DOCK2, DNM1L, INPP5D, MAPK1, 
MAP2K1, PAK1, PIKFYVE, PIK3CG, PIK3R5, PLCG1, PRKCB, PRKCE, 
PTPRC, SYK, LYN, VASP, VAV3, PIK3R1, RAF1, AKT2
Chemokines signaling pathway 4.70E-07 9.30E-06
CXCL16, CXCR4, CXCR1, CXCR2, JAK2, ROCK2, ADCY6, ADCY7, 
ADCY9, ADRBK2, DOCK2, FOXO3, GRB2, GNB4, GNG12, GNG2, 
MAPK1, MAP2K1, NRAS, PAK1, PIK3CG, PIK3R1, PIK3R5, PRKCB, 
PRKX, STAT2, STAT5B, ROCK1, SOS1, SOS2, BRAF, VAV3
Toll-like receptors signaling pathway 3.10E-06 4.30E-05 TLR1, TLR5, TLR2, TLR4, TLR6, TLR7, TBK1, IKBKE, JUN, MAPK1, MAP2K1, MAP2K4, MYD88, PIK3CG, PIK3R1, PIK3R5, FOS
MTOR signaling pathway 5.20E-05 3.80E-04 MTOR, RICTOR, HIF1A, MAPK1, PIK3CG, PIK3R1, PIK3R5, RPS6KA3, TSC1, ULK2, BRAF
Jak-STAT signaling pathway 1.20E-04 7.10E-04
CREBBP, CBL, EP300, JAK1, JAK2, CSF2RB, GRB2, IL10RA, IL13RA1, 
IL6R, IL6ST, PIK3CG, PIK3R1, PIK3R5, PRLR, STAT2, STAT5A, 
STAT5B, SOS1, SOS2, SOCS4, SOCS7
MAPK signaling pathway 4.30E-04 2.10E-03
RAPGEF2, ATF2, DUSP1, DUSP6, FLNB, GRB2, GNA12, GNG12, 
HSPA1A, JUN, MAPK1, MAP2K1, MAP2K4, MAP3K1, MAP4K4, 
NRAS, PAK1, PRKCB, PRKX, RPS6KA3, SOS1, SOS2, TGFBR1, FOS, 
BRAF
ErbB signaling pathway 5.10E-04 2.40E-03
CBL, EREG, GRB2, JUN, MTOR, MAPK1, MAP2K1, MAP2K4, NRAS, 
PAK1, PIK3CG, PIK3R, PIK3CG, PIK3R, PIK3R5, PLCG1, PRKCB, 
STAT5A, STAT5B, SOS1, SOS2, ABL2, BRAF
Insulin signaling pathway 8.30E-04 3.80E-03
CBL, GRB2, INPP5D, IRS2, MTOR, MAPK1, MAP2K1, NRAS, PDE3B, 
PIK3CG, PIK3R1, PIK3R5, PRKCI, PRKX, PTPRF, SOS1, SOS2, SOCS4, 
TSC1, BRAF
Endocytosis 1.00E-03 4.50E-03
ARAP2, ASAP1, ACAP2, CBL, DNAJC6, EHD3, IQSEC1, RAB11, FIP1, 
ADRBK2, CXCR4, CLTCL1, DNM1L, EPN2, HSPA1A, CXCR1, CXCR2, 
LDLR, NEDD4, PIKFYVE, PRKCI, RNF41, SMAP2, TGFBR1, VPS36
Regulation of actin cytoskeleton 2.20E-03 9.60E-03
IQGAP1, IQGAP2, ARHGEF12, ROCK2, ACTN1, CYFIP1, FGFR1, 
FN1, GNA12, GNA13, GNG12, ITGA4, ITGAV, ITGB1, MAPK1, 
MAP2K1, NRAS, PAK1, PIKFYVE, PIK3CG, PIK3R1, PIK3R5, 
PPP1R12A, ROCK1, SSH2, SOS1, SOS2, BRAF, VAV3
Table 3. The downregulated genes involved in immune-related pathways in primary monocytes of XLA 
patients compared to healthy subjects.
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in phagocytosis, DOCK1 (Dedicator of cytokinesis) - involve in kinase activity and DUSP22 (Dual Specificity 
Phosphatase 22) - involve in ubiquitin protease activity.
Gene interaction network of DE lncRNAs with their co-located DE protein-coding genes. To 
unravel the interaction between DE annotated lncRNAs and DE novel lincRNAs and their co-located DE 
protein-coding genes, putative interactive networks were constructed using Cytoscape. The network contained 
80 interactions between 21 DE annotated and DE novel lincRNAs with 23 co-located DE protein-coding genes 
(Fig. 5).
qRT-PCR validation. To further confirm our findings as described above, expression levels of 
selected DE protein-coding genes and DE annotated and novel lincRNAs were measured by Quantitative 
Reverse Transcription Polymerase Chain Reaction (qRT-PCR) analysis. The candidate genes were 10 DE 
protein-coding genes: FCGR2A, CXCR2, TLR1, TLR5, ATP5D, NDUFA1, UQCRB, SOD1, MTOR and BAX 
which were enriched in several significant upregulated and downregulated KEGG pathways. Also included 
were 7 DE annotated lncRNAs; HOTAIRM1, DANCR, GAS5, LINC-PINT, RMRP, HEIH, TUG1 and 3 DE 
novel lincRNAs; TCONS_00041961, TCONS_00295657, TCONS_00298577, which co-located with DE 
protein-coding genes in XLA patients compared to the healthy subjects. The qRT-PCR validation results 
showed that in total, 90% of the selected genes reached significance (P-value ≤ 0.05) (Fig. 6). Comparison 
between RNA-Seq and qRT-PCR log2 fold-change ratio revealed similar expression trends for selected genes 
with a Pearson correlation (r) value of 0.83 (P-value < 0.001), demonstrating the reliability of our RNA-Seq 
data analysis (Fig. 6).
Discussion
In this study, we investigated the effect of BTK gene expression deficiency on primary monocyte’s immune func-
tion in XLA patients using deep RNA-Seq analysis. The BTK gene is situated at band Xq21.3 to Xq22, long arm of 
the X chromosome, spanning 37.5 kb that contains 19 exons. The BTK protein has 5 different functional domains 
including PH, TH, SH3, SH2, and TK. Over 800 mutations have been identified in BTK33. These mutations varied 
in types and scattered throughout all domains of the BTK protein, which all resulting in overall dysfunction of 
BTK protein. Recently, Xia-Fang and colleagues examined the genetic background and clinical features of 174 
patients with XLA and reported that there was no relationship between BTK mutations and clinical symptoms in 
XLA patients34.
We compared transcriptome profiles of primary monocytes of healthy subjects and XLA patients, who 
shared similar clinical symptoms despites having different type of mutations in BTK gene. Our analysis showed 
a total of 1,827 DE protein-coding genes, of which 859 genes were upregulated and 968 genes were downregu-
lated in XLA patients compared to the healthy subjects (Supplementary Table S1). Based on the GO and KEGG 
Figure 3. Interaction network analysis of DE protein-coding genes in primary monocytes of XLA patients 
compared to healthy subjects. The DE protein-coding genes were connected in a network based on the protein-
protein interactions.
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pathways analysis, detailed information on the biological functions and potential mechanisms of actions of 
DE protein-coding genes were identified. The GO enrichment analysis showed that downregulated genes were 
mainly involved in the regulation of immune response. Pathway enrichment analysis also revealed that down-
regulated genes were mainly enriched in several pathways belonged to the innate immune system such as: “Fc 
gamma R-mediated phagocytosis”, “Chemokine signaling pathways”, “Toll like receptors signaling pathway” and 
“MTOR signaling pathway”, reflects the deficiencies of innate immune function in primary monocytes of the 
XLA patients.
The expression of FCGR2A (also known as FcγRIIA or CD32, involved in “Fc gamma R-mediated phago-
cytosis”) was significantly decreased in primary monocytes of the XLA patients which is consistent with the 
findings about decreased expression of FCGR2A in monocytes from XLA patients due to BTK deficiency13. 
In addition to FCGR2A, our study identified the downregulation of 22 core enrichment genes involved in 
“Fc gamma R-mediated phagocytosis” pathway in XLA patients compared to healthy subjects (Table 3). 
Majority of these genes encode for kinases in the early signaling events [such as LYN (LYN Proto-Oncogene, 
Src Family Tyrosine Kinase) and SYK (Spleen Tyrosine Kinase) Kinases] as well as the genes encode for pro-
teins involved in cytoskeleton rearrangement. Decreased expression of 32 core genes involved in “chemokines 
signaling pathway” including 4 chemokine receptors (CXCL16, CXCR1, CXCR2, CXCR4) were also observed 
in primary monocytes of the XLA patients (Table 3). A direct role for BTK in signaling by CXCR4 and in 
chemokine-controlled adhesion and migration in B cells of XLA patients has been shown previously35. Similar 
observations regarding the regulatory role of BTK on CXCR4 as well as CXCL16, CXCR1, and CXCR2 were 
found in primary monocytes of XLA patients in which the BTK deficiency may lead to downregulation of these 
chemokine receptors.
Another significant finding of this study is the overall downregulation of “Toll-like Receptor (TLR) sign-
aling pathway” in primary monocytes of the XLA patients compared to healthy subjects (Table 3). The BTK 
has been shown to be involved in TLR signaling, where it interacted with TLR2, TLR4, TLR6, TLR7, TLR8 and 
TLR9 and facilitated their transduction of downstream signals and phosphorylation10–12. In addition to these 
findings, our study demonstrated for the first time, significant decreased in expression of TLR1 and TLR5 in 
primary monocytes of the XLA patients compared to healthy subjects. This suggested that the BTK may also 
associates with TLR1 and TLR5 expression in primary monocyte of XLA patients, in which mutants of BTK 
may inhibit their signaling. Similar observation of TLR1 signaling deficiency due to the BTK mutant was 
reported in mice36.
Figure 4. The GO and KEGG pathway analysis of DE lncRNAs co-located genes in primary monocytes of 
XLA patients compared to healthy subjects. The significant GO biological process terms enriched for (a) DE 
annotated lncRNAs co-located genes, and (b) DE novel lincRNAs co-located genes. The number of DE lncRNAs 
co-located genes enriched in each GO terms is depicted above the bars in the figure. The significant KEGG 
pathway terms enriched for (c) DE annotated lncRNAs co-located genes, and (d) DE novel lincRNAs co-located 
genes. Each statistical significance value (adj.p-value) was negative log-10 base transformed. The numbers in 
the brackets indicate the total numbers of genes available in the KEGG database for each pathway terms. The 
number of identified DE lncRNAs co-located genes enriched in each KEGG pathways is depicted above the bars 
in the figure.
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Figure 5. The interaction network of DE lncRNAs with their co-located DE protein-coding genes in primary 
monocytes of XLA patients compared to healthy subjects. The DE protein-coding genes were connected in a 
network based on the protein-protein interactions. The edges for lncRNAs that were close in genomic space to 
the DE protein-coding genes were automatically added into the network.
Figure 6. The qRT-PCR validation of DE protein-coding genes and DE lncRNAs in primary monocytes of 
XLA patients compared to the healthy subjects. The comparison of log2 fold-change of DE protein-coding genes 
and DE lncRNAs were determined by RNA-Seq analysis (blue) and qRT-PCR validation (red). PPIA was used 
as endogenous control for normalizing the expression levels. x-axis shows genes; y-axis shows the log2 ratio of 
expression in XLA patients compared to healthy subjects. Statistical significance was calculated using paired 
Student’s T-test. The asterisks above the bars denote statistically significant differences from healthy subjects 
obtained by qRT-PCR, *P-value < 0.05, **P-value < 0.01.
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Our analysis also revealed the downregulation of the MTOR (Mechanistic Target Of Rapamycin) genes along 
with the other 10 core genes of the “MTOR signaling pathway” in the XLA patients compared to healthy subjects 
(Table 3). Recently, Ezell and colleagues reported similar observation regarding the possible regulatory role of 
BTK on MTOR signaling in activated Diffuse Large B Cell Lymphoma (DLBCL)37. MTOR plays an important role 
in cell differentiation and growth, cellular metabolism and cancer metabolism. It can sense the growth factors, 
nutrients, insulin, energy and environmental changes, then transmit signals to downstream targets to activate the 
metabolic and cellular reactions38. In addition, MTOR was recently found to be associated with the regulation 
of both the innate39 and adaptive immune response40. Low expression of MTOR was observed in cells that are 
more dependent on mitochondrial oxidative phosphorylation for energy supply41. Overexpression of mitochon-
drial components due to great energy production demand has been reported in several disease states such as 
cancers42, Acquired Immune Deficiency Syndrome (AIDs)43 and Alzheimer’s disease (AD)44. We also detected 
low expression of MTOR and overexpression of multiple components of mitochondrial complexes I (NDUF; 
NADH: Ubiquinone Oxidoreductase), III (UQCR; Ubiquinol-Cytochrome C Reductase), IV (COX; Cytochrome 
C Oxidase) and V (ATP; Adenosine Triphosphate) in XLA patients compared to the healthy subjects (Table 2). 
This indicate great energy demand in primary monocytes of the XLA patients compared to healthy subjects. 
Furthermore, the upregulated genes involved in the production of reactive oxygen species (ROS), oxidative stress 
response and apoptotic process were observed in the XLA patients compared to healthy subjects. It is well known 
that during the oxidative phosphorylation, mitochondria consume most of the cellular oxygen and produce the 
majority of ROS. High concentration of ROS in the cell would lead to state termed oxidative stress, in which the 
excess ROS induces oxidative damage on cellular components and activate apoptosis pathways and cell death45. 
This may possibly explain the upregulation of several genes involved in the oxidative phosphorylation, ROS pro-
duction, response to oxidative stress and apoptosis in monocytes of XLA patients.
In addition to the protein-coding genes, lncRNAs can also act as key regulators of various biological pro-
cesses in the immune system16, 17. Our analysis of the lncRNAs expression between the XLA patients and healthy 
subjects showed a total of 95 DE annotated lncRNAs (56 upregulated and 39 downregulated) and 20 DE novel 
lincRNAs (5 upregulated and 15 downregulated) (Supplementary Tables S3 and S4). Several DE lncRNAs were 
identified in the XLA patients, which were known to contribute to regulation of gene expressions and cell cycle. 
Overexpression of these lncRNAs have been reported to suppress the cell growth, differentiation, prolifera-
tion, and apoptosis in various diseases. Such lncRNAs include: HOTAIRM126, DANCR27, GAS528, LINC-PINT29, 
HEIH30, RMRP31, which have found to be overexpressed in primary monocytes of the XLA patients compared 
to the healthy subjects. By comparing to healthy subjects, our analysis also detected significant decreased in 
expression of lncRNA TUG1 in the XLA patients. Downregulation of TUG1 has been reported to inhibit osteo-
sarcoma cell proliferation and promote apoptosis32. Similar observation regarding the dysregulated expression 
of these lncRNAs seen in the primary monocytes of XLA patients, suggesting their possible role in regulating 
monocyte cell cycle and apoptosis in XLA patients. The analysis of DE novel lincRNAs also revealed that some 
DE novel lincRNAs were co-located with DE protein-coding genes related to immune system. In particular, the 
novel DE lncRNA TCONS_00030433, which was significantly downregulated in the XLA patients, interacted 
with VAV3, of which its expression was also detected to be downregulated in the XLA patients. VAV3 is known 
to be involved in “Fc gamma R-mediated phagocytosis” pathway46. These results would suggest the possible role 
of TCONS_00030433 in the regulation of “Fc gamma R-mediated phagocytosis” pathway in primary monocytes 
of XLA patients.
In summary, our analysis based on deep RNA-Seq datasets revealed that the expression profiles of 
protein-coding genes were significantly altered in primary monocytes of XLA patients compared to the healthy 
subjects. Regardless type of mutations, loss of function mutation in BTK genes eventually induced dysfunction 
of BTK protein, block the development of B-cell and caused the disease. The functional analysis of differentially 
expressed (DE) protein-coding genes showed that the impaired immune function and increased susceptibility to 
apoptosis in monocytes of XLA patients were due to BTK deficiency. This showed that BTK is not only involved in 
the development and function of B cells, but it may play an important role in establishing the immunity function 
of monocytes. Our study also revealed the differential expression patterns of lncRNAs in primary monocytes of 
XLA patients compared to healthy subjects and predicted their potential role in regulation of monocyte cell cycle 
and apoptosis in XLA patients. However, the specific biological functions and molecular mechanisms of these 
lncRNAs in monocytes of XLA patients required additional evaluation. Moreover, further large scale studies uti-
lising integrated omics approaches would advance our knowledge and understanding on the impaired immune 
function of monocytes in XLA patients.
Methods
Sample collection and purification. Ethics approval to conduct this study was obtained from Medical 
Research and Ethics Committee (MREC), Malaysia with reference number NMRR-13-972-16921. Three unre-
lated male patients with XLA disease and 3 unrelated healthy male subjects were selected in this study. The 
written informed consent from all subjects for the use of their blood samples were obtained. The blood samples 
were handled according to the guidelines of the Helsinki Declaration. The entire experiment was conducted 
in accordance with the guidelines of Medical Research and Ethics Committee (MREC), Malaysia. The healthy 
subjects were non-smokers, did not have any medical illness, did not prescribed with any long-term medication 
and did not receive any vaccination at least 6 months before the study. The patients were diagnosed to have 
XLA disease based on the criteria of the World Health Organization Scientific Group for PIDs: low levels of 
circulating B cells (measured by levels of CD19+ B cells in blood samples), reduced or absent of immunoglob-
ulins in serum and a typical clinical history with recurrent bacterial infection or a positive family history47. All 
selected patients had deficient monocyte BTK expression, as evaluated by flow cytometry. BTK gene mutations 
in all patients were confirmed by Sanger sequencing. All the patients were in a stable clinical situation without 
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fever and not hospitalized when the blood was taken. They were under monthly IVIG therapy. The blood sam-
ples from patients were collected before the administration of IVIG. The 10 mL of peripheral blood from each 
healthy subjects and XLA patients were collected in EDTA tubes. Peripheral blood mononuclear cells (PBMCs) 
were isolated using Ficoll-based density gradient centrifugation. The classical monocytes (CD14++CD16−) were 
isolated from PBMCs by negative selection method using monocyte isolation kit II (Miltenyi Biotec, Germany). 
The BD FACSCanto II Flow Cytometer (BD Biosciences, USA) was used to perform the purity check of the 
isolated monocytes.
RNA extraction, library preparation and sequencing. Total RNA was extracted from monocytes 
using RNeasy mini-kit followed by DNase treatment (QIAGEN, Germany). The quality and quantity of RNA 
was measured using NanoDrop 2000 (Thermo Fisher Scientific Inc, USA) and Qubit 2.0 RNA Broad Range 
Assay (Invitrogen, USA). The RNA purity was checked using Agilent Bioanalyzer RNA Nano chip Bioanalyzer 
(Agilent Technologies, USA). All samples had RNA Integrity Number (RIN) higher than 9. Messenger RNA 
isolation and cDNA synthesis were performed using TruSeq RNA Sample Preparation Kit (Illumina, USA) and 
Super Script II Reverse Transcriptase (Invitrogen, USA). The synthesized cDNA was quantified using Qubit 
2.0 DNA Broad Range Assay (Invitrogen, USA). A minimum of 40ng cDNA was fragmented using Covaris 
S220 (Covaris INC, USA) to a targeted size of 200–300 bp. The fragmented cDNA was then end-repaired, 
ligated to Illumina TruSeq adaptors, and PCR-enriched using TruSeq RNA sample preparation kit (Illumina, 
USA). The final sequencing libraries were quantified using KAPA kit (KAPA Biosystem, USA) on Agilent 
Stragene Mx-3005p quantitative PCR (Agilent, USA) and sizes were confirmed using Agilent Bioanalyzer High 
Sensitivity DNA Chip (Agilent, USA). The RNA libraries were sequenced on Illumina HiSeq 2000 Platform 
(Illumina, USA) to generate 2 × 100 bp paired-end sequencing reads. The quality of sequences in fastq for-
mat was evaluated using FASTQC48. Low quality bases and adaptors were trimmed from the sequences using 
Trimmomatic49.
Alignment and transcript assembly. Quality trimmed sequences from all samples were separately 
mapped to the human reference genome sequence (Ensemble GRCh38.79) using HISAT (version 0.1.4)50 with 
GENCODE junctions as a guided reference annotation and the transcript assembly was performed with StringTie 
(version 1.3.3)51 using a GENCODE reference annotation (version 22). The transcripts abundance was estimated 
as fragments per kilobases of exon per million fragments mapped (FPKM)52. The assembled transcripts of XLA 
patients and healthy subject were separately merged by using Cuffmerge (a part of cufflinks, version 2.2.1)52. The 
merged assembled files were then compared with a GENCODE reference annotation file (version 22) to obtain 
the number of expressed protein-coding genes and lncRNAs in the XLA patients and healthy subjects.
Identification of novel long intergenic non-coding RNAs (lincRNAs). Using an established pipeline 
for identification of lncRNA24, we analyzed the expression of putative novel long intergenic non-coding RNAs 
(lincRNAs) in primary monocytes. Briefly, transcripts with coverage of 3 x and above were filtered from the 
patients and healthy subjects’ transcripts assembled files. Then the filtered transcript files of each dataset were 
separately merged to form a non-redundant set of transcripts using Cuffmerge. The expression level of each 
transcript was quantified using Cuffquant (a part of Cufflinks, version 2.2.1)52 and normalized for total number 
of reads using Cuffnorm (a part of Cufflinks, verstion 2.2.1)52. The transcripts were mapped to the known gene 
annotation from GENCODE (version 22) and categorized as protein-coding, lncRNAs, novel and others (such 
as tRNAs, microRNAs, pseudogenes, etc). All known transcripts were filtered out while novel transcripts were 
retained. Only novel transcripts with more than 200 nucleotides which are intergenic to any GENCODE tran-
script were considered for further analysis. The coding potential of transcripts was then evaluated using Coding 
Potential Assessment Tool (CPAT)53. Coding probability cut-off of 0.375 was used to mark any putative protein 
coding sequences and the sequences were excluded from our analysis. The nucleotide sequences of putative novel 
lincRNAs were searched for any matching sequences against the non-redundant (NR) database from NCBI using 
BLASTN and no significant homology was found.
Differential gene expression analysis. Differential gene expression analysis was performed by employ-
ing Cuffdiff (a part of Cufflinks, version 2.2.1)52. The DE genes were identified with q-value ≤ 0.01 and log2 
fold-change ≥ 1 or ≤ −1. Hierarchical clustering of the expression profiles of detected DE protein-coding genes 
and DE lncRNAs were done with the heatmap function in the R “NMF” package54 using Pearson Correlation.
GO and KEGG pathway analysis of DE protein-coding genes. To investigate the biological impor-
tance of the identified DE protein-coding genes, DAVID (Database for Annotation, Visualization and Integrated 
Discovery) functional annotation tool55 was used to perform Gene Ontology (GO) analysis56. DAVID uses mod-
ified Fisher’s exact test (known as EASE)57 to measure enrichment against a background gene list and adjusting 
the resulting p-values (adj.P-value) using a Benjamini-Hochberg method58. The GO analysis was restricted to 
the category of biological processes as it is the most prominent for evaluation of genes function. The DAVID 
category-GOTERM_BP_FAT level was selected for displaying the results. The minimum number of genes for 
enrichment in each category was set at 2 and the significance cutoff was adj.P-value < 0.01. Subsequently, the 
pathway analysis of identified protein-coding genes was conducted by applying the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) database59 in DAVID tool using the same parameters.
Co-location analysis DE lncRNAs with protein-coding genes. lncRNAs are presumed to regulate 
the expression of their neighboring genes (co-located genes)60. To predict the function of DE lncRNAs through 
their co-located genes, the genomic coordinates of DE lncRNAs were imported to Genomic Regions Enrichment 
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of Annotations Tool (GREAT)61. The GO and KEGG pathway analysis of DE lncRNAs co-located genes was per-
formed using the DAVID functional annotation tool.
The identified co-located genes were then matched with DE protein-coding genes to obtain a lncRNAs 
co-located genes which were also differentially expressed between XLA patients and healthy subjects62.
Gene interaction network construction. In order to predict the DE protein-coding genes interaction, 
the protein-protein interaction network was constructed using Cytoscape plug-in GeneMANIA63 for genes which 
were significantly enriched (adj.P-value < 0.01) in upregulated and downregulated KEGG pathways. In addition, 
gene interaction networks between two subgroups of genes (DE lncRNA and their co-located DE protein-coding 
genes) were also constructed using Cytoscape64. The possible protein-protein interactions between DE 
protein-coding genes in each subgroup was predicted using the Cytoscape plug-in GeneMANIA. The network 
edges automatically added for lncRNAs that were close in genomic space to the DE protein-coding genes.
Validation of RNA-Seq results by qRT-PCR. The expression levels of selected DE protein-coding 
and DE lncRNAs were validated using Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) anal-
ysis. First-strand cDNA was synthesized from 300 ng of RNA from each sample by using the High Capacity 
RNA to cDNA Kits (Applied Biosystems, USA). All the primers and probes for Taqman® Real-time PCR (Life 
Technologies, USA) were designed by Applied Biosystems (Supplementary Table S7). Expression of target genes 
was assessed using the QuantStudio™ 12 K Flex Real-Time PCR System. The conditions of the PCR cycle condi-
tions were: 50 °C for 2 minutes, 95 °C for 20 seconds, followed by 40 cycles of 95 °C for 3 seconds, and 40 cycles of 
60 °C for 30 seconds. Each gene was analyzed in triplicates for each sample. PPIA (Peptidylprolyl Isomerase A) 
gene was used as an endogenous control. Fold-changes in gene expression between samples were calculated using 
2−ΔΔCt method65. The Student’s t-test was used to evaluate the expression differences of selected protein-coding 
genes and lncRNAs between XLA patients and healthy subjects. P-value < 0.05 was considered as statistically 
significance.
Availability of data and materials. The data discussed in this publication have been deposited in NCBI’s 
Gene Expression Omnibus (GEO) and are accessible through GEO series accessions number GSE80095 and 
GSE89980.
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